What is Zevra Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zevra Therapeutics's interest expense for the
three
months ended in Dec. 2024 was $ -2.19 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-7.35 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zevra Therapeutics's Operating Income for the
three
months ended in Dec. 2024 was $ -15.42 Mil. Zevra Therapeutics's Interest Expense for the
three
months ended in Dec. 2024 was $ -2.19 Mil.
Zevra Therapeutics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Zevra Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (NAS:ZVRA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Zevra Therapeutics's Interest Expense for the
three
months ended in Dec. 2024 was $-2.19 Mil. Its
Operating Income
for the
three
months ended in Dec. 2024 was $-15.42 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2024 was $59.88 Mil.
Zevra Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
| Zevra Therapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Zevra Therapeutics Business Description
Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Executives
| Neil F. Mcfarlane |
director, officer: President and CEO |
C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
| R. Laduane Clifton |
officer: VP Fin & Corp Controller |
C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747 |
| Joshua Schafer |
officer: CCO & EVP, Bus. Development |
SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850 |
| Timothy J. Sangiovanni |
officer: VP, Corporate Controller |
C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241 |
| Watton Corey Michael |
director |
22045 KAREN STREET, ELKHORN NE 68022 |
| Thomas Anderson |
director |
215 FIRST STREET, CAMBRIDGE MA 02142 |
| John B Bode |
director |
C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012 |
| Douglas W Calder |
director |
324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
| Wendy L Dixon |
director |
|
| Tamara A Seymour |
director |
C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
| Matthew R Plooster |
director |
2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
| David S Tierney |
director |
C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
| Richard W Pascoe |
director |
C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
| Christopher Posner |
director |
C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
| Travis C Mickle |
director, 10 percent owner, officer: President & CEO |
2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
Zevra Therapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVRA has been successfully added to your 